Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06312137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06312137 · ClinicalTrials.gov record · last posted 2026-08-21

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Study acronym: TroFuse-019
StatusRecruiting
PhasePhase 3
Started2024-04-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Protocol amendment history 1 change detected by DataLookout

2026-05-16
Trial sites expanded: 260 → 263 locations
Trial Details
NCT Number NCT06312137
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non Small Cell Lung Cancer
Enrollment 780 participants
Start Date 2024-04-03
Primary Completion 2034-02-21 (estimated)
Study Completion 2034-10-23 (estimated)
Updated on ClinicalTrials.gov 2026-08-21